Current recommendations for chelation for transfusion-dependent thalassemia.

Area of Science:

• Hematology
• Pharmacology
• Internal Medicine

Background:

• Thalassemia necessitates regular red blood cell transfusions, leading to iron loading.
• Iron overload significantly contributes to morbidity and mortality in thalassemia major.
• Chelation therapy is essential for removing excess iron and preventing organ damage.

Purpose of the Study:

• To review the current landscape of chelation therapy for thalassemia.
• To discuss the role of monotherapy versus combination therapy.
• To highlight factors influencing treatment selection and the impact of newer chelator combinations.

Main Methods:

• Review of available iron chelators: deferoxamine, deferasirox, and deferiprone.
• Discussion of monotherapy and combination therapy strategies.
• Emphasis on monitoring hepatic and cardiac iron burden.

Main Results:

• Adequate chelation therapy is critical for reducing morbidity and mortality.
• Combination chelation is often necessary for high iron burden or organ injury.
• Newer chelator combinations show promise for improved iron burden control.

Conclusions:

• The choice of chelation therapy (mono- or combination) should be individualized.
• Monitoring iron burden is key to effective management.
• An expanding range of chelators offers potential for better outcomes in thalassemia.